Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer (pages 5309–5318)
Zhiqiang Meng, Peiying Yang, Yehua Shen, Wenying Bei, Ying Zhang, Yongqian Ge, Robert A. Newman, Lorenzo Cohen, Luming Liu, Bob Thornton, David Z. Chang, Zongxing Liao and Razelle Kurzrock
Version of Record online: 21 AUG 2009 | DOI: 10.1002/cncr.24602
A pilot study was conducted, using a phase 1 trial design, of huachansu (a Chinese medicine that comes from dried toad venom from the skin glands of Bufo gargarizans or B. melanostictus) in patients with advanced cancer. There were no dose-limiting toxicities even at doses up to 8× higher than typically used in China; 6 patients had prolonged stable disease or minor tumor shrinkage.